Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Axitinib
Drug ID BADD_D00193
Description Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta？ and is available in oral formulations.
Indications and Usage Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Marketing Status Prescription
ATC Code L01EK01
DrugBank ID DB06626
KEGG ID D03218
MeSH ID D000077784
PubChem ID 6450551
TTD Drug ID D01ZRI
NDC Product Code 54893-0043; 68554-0088; 54893-0032; 65344-0033; 63539-044; 0069-0151; 0069-0145; 63539-026
Synonyms Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta
Chemical Information
Molecular Formula C22H18N4OS
CAS Registry Number 319460-85-0
SMILES CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood sodium decreased13.11.01.012--Not Available
Blood thyroid stimulating hormone increased13.10.03.0060.004263%
Blood triglycerides increased13.12.03.0010.000799%Not Available
Blood urea increased13.13.01.0060.002131%Not Available
Blood uric acid increased13.02.04.0010.000533%Not Available
Bone pain15.02.01.0010.002131%
Bradycardia02.03.02.002--Not Available
Brain stem infarction17.08.01.024; 24.04.06.0140.000533%Not Available
Bronchopulmonary aspergillosis11.03.01.002; 22.07.08.0010.000278%Not Available
Burning sensation08.01.09.029; 17.02.06.001--Not Available
C-reactive protein increased13.09.01.0070.002131%Not Available
Cachexia08.01.01.009; 14.03.02.001; 16.32.03.0110.000139%Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.0010.001529%
Cardiac failure acute02.05.01.0050.000533%Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest02.03.04.002; 22.02.06.007--Not Available
Cardiomyopathy02.04.01.001--Not Available
Cardiovascular disorder02.01.01.001; 24.03.02.009--Not Available
Cataract06.06.01.001--
Cellulitis11.02.01.001; 23.09.01.001--Not Available
Cerebral haemorrhage17.08.01.003; 24.07.04.001--Not Available
Cerebral infarction17.08.01.004; 24.04.06.0020.004795%Not Available
Cerebral ischaemia17.08.01.005; 24.04.06.0030.000799%
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Chest discomfort02.02.02.009; 08.01.08.019; 22.02.08.001--Not Available
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.003--Not Available
Chills08.01.09.001; 15.05.03.016--
Choking22.02.05.0010.000208%Not Available
Cholangitis09.02.01.0020.001598%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 19 Pages